General Introduction
The Department of Hepatobiliary Surgery at Tianjin Medical University Cancer Institute and Hospital (TMUCIH) has a long history of being at the forefront of education, research, and clinical care. The department of hepatobiliary surgery deals with the diagnosis, treatment and management of benign and malignant diseases of the liver, pancreas, biliary tract, spleen and allied diseases. The department currently staffs 118 general beds. Nearly 20,000 out-patients visit the department each year, among which 4,000 are admitted in the in-patient department, and over 2,000 operations have been performed per year. The mission of the department is to provide excellent patient care in an environment that stimulates its faculty, trainees and students to constantly improve their patient care, teaching, learning and investigation abilities.
Faculty / Staff
The department includes 17 surgeons and 1 scientific researcher. All the
surgeons are training representing the entire spectrum of surgical experience,
including the director Tianqiang Song, three chief physician, four associate
chief physicians and nine doctors with PhD degree.
Research
The departments also attach importance to the research of transformational
medicine and strengthen the cooperation with relevant basic research
departments. At present, there are 4 projects of the National Natural Science Foundation of China (NSFC), 3 major
sub-projects of the The National Science and Technology Major Project of China,
and 2 projects of The Science & Technology Development Fund of Tianjin
Education Commission for Higher Education. Between 2016 and 2018, 17 SCI papers
and 7 Chinese series magazines were published, 9 other core journals were
published. In 2017, the project of "Basic and Clinical Integration
Research on Heterogeneity of Malignant Tumors such as Hepatocellular
Carcinoma" was selected as the "13th Five-Year Plan" for the
Promotion of Advantage Disciplines in the Construction of Comprehensive
Investment Disciplines.
Clinical Service
The Department of Hepatobiliary Surgery focuses on
primary, secondary hepatocellular carcinoma, cholangiocarcinoma and gallbladder
cancer. The development of technology has always been our goal. Accurate
hepatobiliary tumor resection, laparoscopic hepatobiliary tumor resection,
robotic hepatobiliary tumor resection, including percutaneous, laparoscopic and
laparotomy radiofrequency ablation have been routinely carried out. The establishment of MDT team for hepatobiliary tumors in 2011 has been
running successfully so far. It is one of the three best teams for MDT
development and the earliest department for rapid rehabilitation surgery in the
hospital (2007). At present, ERAS concept has been widely developed in the
department of Hepatobiliary Surgery and has become a conventional technology.
The undergraduate has abundant clinical case resources, and has established a
complete tissue specimen bank, serum specimen bank and clinical pathological
data database. At present, it undertakes 12 international and domestic
multi-center clinical trials. It is one of the earliest surgical departments in
the hospital to carry out clinical trials. All doctors have GCP certification. In
2017, Postoperative adjuvant chemotherapy for biliary tract tumors was selected
as one of the three key projects in the hospital's clinical research.
